Clinical characteristics and risk factors associated with nosocomial COVID-19 infection in patients with hematological disorders in Japan
Abstract Patients with cancer are considered at high risk of acquiring coronavirus disease (COVID-19). To identify patients who are likely to be diagnosed with severe COVID-19, we analyzed the risk factors for mortality in patients admitted to the hematology department at our institute. The mortality rate of all patients was as high as 62% (21 of the 34 patients), and most of these patients had malignant malignancies. Patients before an achievement of remission had a 10.8-fold higher risk of death than those in remission. The group receiving chemotherapy with steroids had a shorter survival time and had an 8.3-fold higher risk of death than that receiving chemotherapy without steroids. During the COVID-19 pandemic, it is necessary to carefully monitor or follow-up patients with active diseases and patients receiving steroid-containing chemotherapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:114 |
|---|---|
| Enthalten in: |
International journal of hematology - 114(2021), 6 vom: 21. Juni, Seite 719-724 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ohara, Shin [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
COVID-19 |
| Anmerkungen: |
© Japanese Society of Hematology 2021 |
|---|
| doi: |
10.1007/s12185-021-03172-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR045453187 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR045453187 | ||
| 003 | DE-627 | ||
| 005 | 20230519084245.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211101s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12185-021-03172-0 |2 doi | |
| 035 | |a (DE-627)SPR045453187 | ||
| 035 | |a (SPR)s12185-021-03172-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.86 |2 bkl | ||
| 100 | 1 | |a Ohara, Shin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical characteristics and risk factors associated with nosocomial COVID-19 infection in patients with hematological disorders in Japan |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Japanese Society of Hematology 2021 | ||
| 520 | |a Abstract Patients with cancer are considered at high risk of acquiring coronavirus disease (COVID-19). To identify patients who are likely to be diagnosed with severe COVID-19, we analyzed the risk factors for mortality in patients admitted to the hematology department at our institute. The mortality rate of all patients was as high as 62% (21 of the 34 patients), and most of these patients had malignant malignancies. Patients before an achievement of remission had a 10.8-fold higher risk of death than those in remission. The group receiving chemotherapy with steroids had a shorter survival time and had an 8.3-fold higher risk of death than that receiving chemotherapy without steroids. During the COVID-19 pandemic, it is necessary to carefully monitor or follow-up patients with active diseases and patients receiving steroid-containing chemotherapy. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hematological disorders |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chemotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nosocomial infection |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Fujii, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Ide, Shiro |e verfasserin |4 aut | |
| 700 | 1 | |a Uchida, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Morihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hagaihara, Masao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of hematology |d Tokyo [u.a.] : Springer, 1995 |g 114(2021), 6 vom: 21. Juni, Seite 719-724 |w (DE-627)SPR025085697 |w (DE-600)2028991-1 |x 1865-3774 |7 nnns |
| 773 | 1 | 8 | |g volume:114 |g year:2021 |g number:6 |g day:21 |g month:06 |g pages:719-724 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12185-021-03172-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.86 |q ASE |
| 951 | |a AR | ||
| 952 | |d 114 |j 2021 |e 6 |b 21 |c 06 |h 719-724 | ||